<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083416</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21150</org_study_id>
    <secondary_id>20121102</secondary_id>
    <nct_id>NCT05083416</nct_id>
  </id_info>
  <brief_title>Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome</brief_title>
  <official_title>Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate if eating within an 8-10-hour window during the day, without any&#xD;
      caloric restriction, can lead to better response rates to immunotherapy in head and neck&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Prolonged Nightly Fasting (PNF) compliance</measure>
    <time_frame>at 3 months</time_frame>
    <description>Adherence to the 8-10 hour time restricted feeding window will be measured using &quot;mycircadianclock&quot; app ,which has been validated as a tool to conveniently and reliably track time of food intake and its correlation with timing of the day and sleep. It can be tailored to restrict feeding duration to specific set points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gut microbiome and microbial metabolites</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
    <description>Changes in gut microbiome composition/diversity as well as gut microbial metabolites in participants using PNF will be compared with participants that are not restricting eating times will be measured using stool samples.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>A: Prolonged Nightly Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be educated on Prolonged Nightly Fasting (PNF) and be allowed to choose any 10-hr period that falls between 6 AM- 6 PM, as feeding period. Participants will be recommended to follow study diet guidelines, eat to satiety and not count calories. Participants will be allowed to have water, beverages (&lt;4 kcal) during the fasting period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Regular Eating pattern</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will follow a traditional eating pattern with no time restrictions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Nightly Fasting</intervention_name>
    <description>Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.</description>
    <arm_group_label>A: Prolonged Nightly Fasting</arm_group_label>
    <other_name>Intermittent Fasting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Regular Eating pattern</intervention_name>
    <description>Food intake not limited to a specific time during day/night.</description>
    <arm_group_label>B: Regular Eating pattern</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed recurrent /metastatic head and neck squamous cell cancer that is not&#xD;
             amenable to local therapy with curative intent (surgery or radiation therapy with or&#xD;
             without chemotherapy) and initiating standard of care immune checkpoint blocker-&#xD;
             (Nivolumab, pembrolizumab, Atezolizumab, Avelumab or Durvalumab with or without&#xD;
             chemotherapy), for the first time.&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as&#xD;
             outlined in RECIST version 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI&lt; 18.5.&#xD;
&#xD;
          -  Diabetes mellitus, hyperthyroidism, pregnancy, any eating disorder including anorexia&#xD;
             nervosa or bulimia, metabolic disorders that may affect gluconeogenesis or adaptation&#xD;
             to short fasting periods&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, autoimmune disease requiring systemic steroids, symptomatic congestive&#xD;
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          -  Patients who have known leptomeningeal metastases or untreated or symptomatic brain&#xD;
             metastases. Treated, asymptomatic brain metastasis can be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jameel Muzzaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Hodge</last_name>
      <phone>813-745-4901</phone>
      <email>Eli.Hodge@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jameel Muzaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahla Bari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Conejo-Garcia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kedar Kirtane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Kish, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent Fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

